TrialCancer immunology research2026

A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.

Katherine M Bever et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.